Search Results
Your search for multiple myeloma matches 1442 pages
Showing 1401 - 1442Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...
Body Mass Index Positively Associated With Many Cancers in UK Study
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma
The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...
Improved Survival in Hematologic Malignancies in Europe Between 1997 and 2008
As reported by Sant et al in The Lancet Oncology, the population based EUROCARE-5 study has shown significantly improved survival in hematologic malignancies in Europe between 1997 and 2008. Although improved, survival was poorer in Eastern Europe compared with other regions. Study Details This...
Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation Effective in Multiple Myeloma in French Phase II Trial
In a phase II Intergroupe Francophone du Myélome (IFM) trial reported in the Journal of Clinical Oncology by Roussel et al, induction and consolidation treatment with RVD (lenalidomide [Revlimid], bortezomib [Velcade], and dexamethasone) followed by lenalidomide maintenance was associated...
High-Dose Melphalan Plus Autologous Stem Cell Transplantation as Consolidation Shows Benefit in Relapsed Multiple Myeloma After Previous Transplant
In a UK phase III trial (NCRI Myeloma X Relapse [Intensive] Trial) reported in The Lancet Oncology, Cook et al found that high-dose melphalan plus salvage autologous stem cell transplantation significantly prolonged time to progression vs cyclophosphamide in patients with relapsed multiple myeloma...
FDA Grants Orphan Drug Designation to ENMD-2076 for Hepatocellular Carcinoma
CASI Pharmaceuticals, Inc, announced that its investigational agent ENMD-2076 has received orphan drug designation from the U.S. Food & Drug Administration (FDA) for the treatment of hepatocellular carcinoma. ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor with a unique...
Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones
A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...
Combined Index Predicts Early Multiple Myeloma Progression-Related Death in Patients Receiving Front-Line Autologous Stem Cell Transplantation
In a European study reported in the Journal of Clinical Oncology, Moreau et al developed and validated a combined index for prognosis in patients with multiple myeloma treated with front-line autologous stem cell transplantation. The index, consisting of high lactate dehydrogenase (LDH) level,...
Immunotherapy May Be Effective in the Treatment of Multiple Myeloma
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma. The findings by ...
Investigational Bromodomain Inhibitor Shows Clinical Activity in Some Blood Cancers
The results from a phase I study of a new investigational epigenetic therapy called OTX015, a small-molecule inhibitor that blocks the activity of bromodomain and extraterminal (BET)-bromodomain proteins, is showing clinical activity in some blood cancers, including leukemia and lymphoma. The study ...
African Americans Have Higher Prevalence of Multiple Myeloma Precursor Than Whites and Hispanics
A large population-based study by Landgren et al has found that African Americans are more likely to have a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor to the development of multiple myeloma, compared with whites or Hispanics. The study is published...
New Finding Points to Potential Options for Targeting Stem Cells in Triple-Negative Breast Cancer
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University has found that a protein that regulates an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This finding may provide a potential target for...
Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for CLL
In response to FDA's approval earlier this week of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL) who had received at least one prior therapy, The Leukemia & Lymphoma Society (LLS) issued the following statement: "After the FDA designated ibrutinib as a...
Lenalidomide, Particularly When Combined With Oral Melphalan, Increases Risk of Second Primary Hematologic Malignancy in Myeloma Therapy
Lenalidomide (Revlimid) has been associated with risk for second primary malignancies in patients with myeloma. In a meta-analysis of individual patient data reported in The Lancet Oncology, Palumbo et al found that lenalidomide was associated with a significantly increased risk of second primary...
Improved Survival With Four-Drug Induction Regimen Followed by Maintenance in Initial Treatment of Transplant-Ineligible Multiple Myeloma
In an updated analysis of an Italian phase III trial reported in the Journal of Clinical Oncology, Palumbo et al found that induction with bortezomib (Velcade), melphalan, prednisone, and thalidomide (Thalomid) followed by bortezomib plus thalidomide maintenance (VMPT-VT) significantly improved...
Multiple Myeloma Study Shows Widespread Genetic Heterogeneity
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
No Survival Benefit for Tecemotide After Chemoradiotherapy in Stage III NSCLC
In the phase III START trial reported in The Lancet Oncology, Butts et al assessed whether maintenance treatment with the MUC1 antigen–specific immunotherapy tecemotide could prolong overall survival in patients with unresectable stage III non–small cell lung cancer (NSCLC) who had...
U.S. Cancer Death Rates Continue Decline, Annual Report Shows
Maintaining a 2 decade–long trend, the cancer death rate in the United States continues to decline, according to the Annual Report to the Nation on the Status of Cancer, published online this week in Cancer. The report, which covers the years 2001 to 2010, shows drops in death rates for a...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
Continuous Lenalidomide/Low-Dose Dexamethasone Improves Survival vs Standard Treatment in Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using continuous treatment with the doublet of lenalidomide (Revlimid) and low-dose dexamethasone was superior to standard triplet treatment with melphalan, prednisone, and thalidomide (Thalomid) for 72 weeks, according to initial results of...
Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma
A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...
Multiple Myeloma Defined by Light Chain Amyloidosis With Plasma Cell or CRAB Criteria
In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...
Addition of Vorinostat to Bortezomib Results in Small Progression-Free Survival Advantage in Previously-Treated Multiple Myeloma
In a phase III study (VANTAGE 088 trial) reported in The Lancet Oncology, Meletios Dimopolous, MD, of the University of Athens, and colleagues assessed the addition of the oral HDAC inhibitor vorinostat (Zolinza) to bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma. The...
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
Pomalidomide Produces ‘Impressive Results’ in Patients With Multiple Myeloma Who Are Refractory to Bortezomib and Lenalidomide
The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide and bortezomib,” according to a review of clinical data leading to the drug’s approval by the U.S. Food and Drug...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Pomalidomide Plus Low-Dose Dexamethasone Improves Survival vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Pomalidomide (Pomalyst) alone has shown limited efficacy in relapsed multiple myeloma, but synergistic effects have been noted when it is combined with dexamethasone. In a phase III trial (MM-003) reported in The Lancet Oncology, Jesus San Miguel, MD, of Universidad de Salamanca, and colleagues...
Panobinostat Combined With Bortezomib and Dexamethasone Can Recapture Responses in Heavily Pretreated Patients With Multiple Myeloma
The combination of the investigational histone deacetylase inhibitor panobinostat (Faridak) with bortezomib (Velcade) and dexamethasone was able to recapture responses in 34.5% of heavily pretreated, bortezomib-refractory patients with multiple myeloma in the phase II PANORAMA 2 trial. The 55...
Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic ...
Gene That Helps Control Aging Is Linked to Multiple Myeloma
A telomerase RNA component gene called TERC, which is responsible for regulating the length of caps on the ends of DNA molecules and believed to be involved in the aging process, has been linked to the development of multiple myeloma, according to a study published in Nature Genetics. Researchers...
Lenalidomide plus Dexamethasone Delays Progression and Improves Survival in High-risk Smoldering Multiple Myeloma
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
Height Significantly Linked to Cancer Risk in Postmenopausal Women
An analysis of data from the Women’s Health Initiative (WHI) of the height measurement at enrollment of 144,701 postmenopausal women and the risk of all cancers combined has found that 20,928 of the women had a diagnosis of one or more invasive cancers during a median follow-up of 12 years....
Cancer Survivors Might Have a Decreased Risk for Alzheimer's Disease
The results from a large cohort study of 3.5 million veterans in the Veterans Affairs (VA) Boston Healthcare System show that most types of cancer were associated with a reduced risk of developing Alzheimer’s disease of between 9% and 51%. The cancers associated with the greatest reduction in ...
New Guidelines Issued in the Treatment of Multiple Myeloma–related Bone Disease
The International Myeloma Working Group (IMWG) has developed clinical practice recommendations for the management of multiple myeloma–related bone disease based on published study data through August 2012. Consensus of the interdisciplinary panel of clinical experts on the plasma-cell...
Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients
A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...
Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm
In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...
Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma
FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...
Risk of Leukemia After Cancer Chemotherapy Persists
While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...
AACR Hosts Congressional Briefing on Cancer Progress, NIH Funding
The American Association for Cancer Research (AACR) hosted a briefing on February 12 for members of Congress and their legislative staffs that highlighted progress in cancer research and treatment as well as challenges created by decreased levels of funding. The briefing was held in the Rayburn...
FDA Approves Pomalidomide for Advanced Multiple Myeloma
The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...
Experimental Drug Combination Selectively Destroys Lymphoma Cells
Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...
